Myrislignan

J Nat Med. 2017 Jan;71(1):76-85.

The action and mechanism of myrislignan on A549 cells in vitro and in vivo.[Pubmed: 27491743 ]

Myrislignan is a natural compound with little pharmacological study. In our investigation, we investigated the effect of Myrislignan in the induction of apoptosis in A549 cells in vitro and in vivo.
METHODS AND RESULTS:
Myrislignan inhibited the proliferation of A549 cells in a dose- and time-dependent manner assayed by MTT. In addition, Hoechst flow cytometry showed that Myrislignan significantly induced apoptosis and cell cycle arrest in A549 cells. The apoptosis and anti-cell proliferation was mediated by the activation of mitogen-activated protein kinase and the inhibition of epidermal growth factor receptor signal pathway, change of mitochondrial membrane potential, the releasing of c-Myc, the downregulation of the level of the anti-apoptotic protein Bcl-2, and the upregulation of the level of the pro-apoptotic protein Bax.
CONCLUSIONS:
In conclusion, those results reveal a potential mechanism for the anti-cancer effect of Myrislignan on human lung cancer, while suggesting that Myrislignan may be a promising compound for the treatment of lung cancer.

Food Chem. 2015 Apr 15;173:231-7.

New neolignans from the seeds of Myristica fragrans that inhibit nitric oxide production.[Pubmed: 25466017]

Five new 8-O-4' type neolignans, named myrifralignan A-E (1-5), together with five known analogues (6-10), were isolated from the seeds of Myristica fragrans Houtt.
METHODS AND RESULTS:
Their chemical structures were determined using several spectroscopic methods. Compounds 3-10 exhibited potent inhibitory activity against the production of nitric oxide (NO) in the RAW264.7 cell line stimulated by lipopolysaccaride. Myrislignan (7) and machilin D (10) were the most potent inhibitors of NO production amongst these compounds. The IC50 values of Myrislignan and machilin D were 21.2 and 18.5 μM. And, their inhibitory activity was more than L-N(6)-(1-iminoethyl)-lysine, a selective inhibitor of inducible nitric oxide synthase (IC50=27.1 μM). Furthermore, real-time PCR analysis revealed that these neolignans could significantly suppress the expression of inducible nitric oxide synthase mRNA.
CONCLUSIONS:
These results demonstrated that the 8-O-4' type neolignans are promising candidates as anti-inflammatory agents.

Phytother Res. 2012 Sep;26(9):1320-6.

Myrislignan attenuates lipopolysaccharide-induced inflammation reaction in murine macrophage cells through inhibition of NF-κB signalling pathway activation.[Pubmed: 22294521]

Myrislignan is a new kind of lignan isolated from Myristica fragrans Houtt. Its antiinflammatory effects have not yet been reported.
METHODS AND RESULTS:
In the present study, the antiinflammatory effects and the underlying mechanisms of Myrislignan in lipopolysaccharide (LPS)-induced inflammation in murine RAW 264.7 macrophage cells were investigated. Myrislignan significantly inhibited LPS-induced production of nitric oxide (NO) in a dose-dependent manner. It inhibited mRNA expression and release of interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α). This compound significantly inhibited mRNA and protein expressions of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) dose-dependently in LPS-stimulated macrophage cells. Further study showed that Myrislignan decreased the cytoplasmic loss of inhibitor κB-α (IκB-α) protein and the translocation of NF-κB from cytoplasm to the nucleus.
CONCLUSIONS:
Our results suggest that Myrislignan may exert its antiinflammatory effects in LPS-stimulated macrophages cells by inhibiting the NF-κB signalling pathway activation.

Biomed Chromatogr. 2008 Jun;22(6):601-5.

Quantification of myrislignan in rat plasma by solid-phase extraction and reversed-phase high-performance liquid chromatography.[Pubmed: 18254153]

METHODS AND RESULTS:
A rapid and simple reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed for determination of Myrislignan in rat plasma after intravenous administration. The analytes extracted from plasma samples by solid-phase extraction were successfully carried out on a Diamonsiltrade mark ODS C(18) column (250 x 4.6 mm i.d., 5 microm) with an RP(18) guard column (8 x 4.6 mm i.d., 5 microm) and a mobile phase of MeOH-H(2)O (4:1, v/v). The UV detector was set at a single wavelength of 270 nm. The linear ranges of the standard curves were 0.5-30.0 microg/mL with the correlation coefficients greater than 0.9992. The lower limits of detection and quantification were 0.1 and 0.3 microg/mL for Myrislignan. Intra- and inter-day precisions were 2.4-7.5 and 1.3-5.7%, respectively. The extraction recovery from plasma was more than 90%.
CONCLUSIONS:
This assay method has been successfully used to study the pharmacokinetics of Myrislignan in rats.